REC Ref No.	IRAS No.	Name of Trial	Date First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
18/WM/0275	211232	A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual- targeted neoadjuvant chemotherapy treatment for HER2- positive, ER-negative early breast cancer can be identified by multiple ultrasound (US)-guided tumour bed core biopsies		14/06/2019	04/12/2019	11/02/2019					
19/LO/1082	254912				12/12/2019						
19/NW/0336	256297	Radiographic imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)		30/09/2019	05/11/2019	07/08/2019					Both NHS Trust and Sponsor
19/LO/1583	271866	A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell Disease	12/12/2019	11/09/2019	18/11/2019	14/11/2019	15/11/2019	26/11/2019		28/11/2019	No delay (met the metric)
19/LO/1566	267041	A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease			21/11/2019	21/11/2019		17/12/2019			No delay (met the metric)
19/NE/0312	266862	AN OPEN LABEL PHASE 1A/B STUDY OF MTL-CEBPA IN COMBINATION WITH A PD-1 INHIBITOR (PEMBROLIZUMAB) IN ADULT PATIENTS WITH ADVANCED SOLID TUMOURS (TIMEPOINT)			15/11/2019						
17/SC/0605	234167	A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX- SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced solid tumours			12/11/2019		43781				
19/LO/1694		A Phase 1/2 Open-Label, Multi-Center, First-in-Human Study of the safety, toleraribility pharmacokinetics, and Anti-tumor activity of TPX-0005 in PAtients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangments			14/12/2019		43663				Sponsor
19/LO/1630	261244	Haemodynamic changes in femoral-popliteal bypass grafts with the use of neuromuscular electrical stimulation			21/11/2019	11/11/2019					
	267131	An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension		12/08/2019	15/11/2019		12/08/2019				
19/LO/1585	263041	Compression Hosiery to Avoid Post-Thrombotic Syndrome			31/10/2019	24/10/2019					

										-
		A Randomized, Double-Blind, Phase 3 Study to Evaluate the		05/07/2019	29/11/2019					
		Activity of Momelotinib (MMB) versus Danazol (DAN) in								
		Symptomatic, Anemic Subjects with Primary Myelofibrosis								
		(PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post								
		Essential Thrombocythemia (ET) Myelofibrosis who were								
		Previously Treated with JAK Inhibitor Therapy.								
19/LO/0855	260338	A Phase 2, randomized, non-comparative, open-label study		03/05/2019	27/06/2019	27/06/2019				Sponsor
		of NKTR-214 in combination with nivolumab and of								
		chemotherapy in cisplatin ineligible, locally advanced or								
		metastatic urothelial cancer patients with low PD L1								
		expression								
16/EM/0186	173279	Can we save the rectum, by watchful waiting ortransanal		12/01/2017		31/10/2016				Both NHS Trust
		surgery following (chemo)radiotherapy versus total								and Sponsor
		mesorectal excision for early rectal cancer?								
17/LO/0232	220795	An Open-Label, Randomized, Crossover Trial utilizing a		30/10/2018	15/04/2019		04/04/2019	17/04/2019	10/06/2019	Both NHS Trust
		Single-Blinded Rater to evaluate APL-130277 compared to								and Sponsor
		s.c. Apomorphine in Levodopa Responsive Subjects with								
		Parkinson's Disease Complicated by Motor Fluctuations								
17/NE/0061	215780	Colchicine for Prevention of Vascular Inflammation in Non-	16/04/2019	08/02/2018	19/02/2019	25/07/2017	06/02/2019	04/03/2019	14/03/2019	
		Cardioembolic Stroke - A Randomised Clinical Trial of Low-	10/01/2010	00,02,2010	10/02/2010	20/01/2011	00,02,2010	0 1/00/2010	1 1/00/2010	
		Dose Colchicine for Secondary Prevention After Stroke								
17/YH/0123	203556	International phase I/II expansion trial of the MEK inhibitor		18/04/2019	23/04/2019	20/12/2017	08/07/2019	17/07/2019	12/08/2019	Sponsor
1771100120		selumetinib in combination with dexamethasone for the		10/04/2010	20/04/2010	20/12/2011	00/01/2010	11/01/2010	12/00/2010	
		treatment of relapsed/refractory RAS-pathway mutated								
		paediatric and adult Acute Lymphoblastic Leukaemia								
18/WM/0006	225107	An Adaptive, Sequential Evaluation of Powered and Manual		20/11/2017	03/07/2019	24/04/2019	15/11/2019	20/11/2019		Sponsor
10/ 11/ 0000	220101	Circular Staplers in Left-Sided Colorectal Anastomoses		25/11/2017	00/01/2010	24/04/2013	10/11/2010	20/11/2013		
19/WA/0010	233205	TALAPRO-2 A Phase 3, Randomized, Double-Blind, Placebo-		28/02/2018	24/04/2019	22/05/2019	43720	02/10/2019	02/10/2019	Sponsor
19/00/10	233293	Controlled Study of Talazoparib with Enzalutamide in		20/02/2010	24/04/2013	22/03/2019	43720	02/10/2019	02/10/2019	oponisoi
		Metastatic Castration-Resistant Prostate Cancer								
17/EM/0440	230556	A randomised phase III trial to evaluate the Duration of ANti-		20/04/2018	23/10/2019	24/05/2018				Neither NHS Trust
1772100/0440	230330	PD1 monoclonal antibody Treatment in patients with		20/04/2010	23/10/2019	24/03/2010				nor Sponsor
		metastatic mElanoma								
18/NE/0210	223922	The Management for Adults with Chronic RhinOsinusitis		43490	26/07/2019	20/07/2018	43676	13/09/2019	43748	NHS Trust
10/11/0210	223922	(MACRO)		43490	20/01/2019	20/07/2010	43070	13/03/2013	43740	
18/NW/0514	240725	SELECT - Semaglutide effects on cardiovascular outcomes		16/07/2019	11/01/2019			06/02/2019		Neither NHS Trust
10/11/0514	249725	-		10/07/2010	11/01/2019			00/02/2019		
17/SC/0434	209815	in people with overweight or obesity BiomArker-guided Duration of Antibiotic treatment in		28/00/2017	17/07/2019	23/10/2017				nor Sponsor Sponsor
17/30/0434	209015	-		20/09/2017	17/07/2019	23/10/2017				oponsoi
		hospitalised PaTients with suspected Sepsis: the ADAPT- Sepsis Trial.								
16/SS/0070	202202	PREvention of Complications to Improve Outcome in elderly		12/07/2010	04/02/2019	42891	01/05/2019	28/05/2019	18/07/2019	Sponsor
10/33/00/0	202282			12/07/2018	04/02/2019	42691	01/05/2019	20/05/2019	10/07/2019	Sponsor
		patients with acute Stroke. A randomised, open, phase III,								
10/00/0045	220005	clinical trial with blinded outcome assessment.			19/00/0040	00/00/0040			 	Changer
	236685	CACZ885T2301			18/06/2019	23/02/2018				Sponsor
17/SW/0250	222991	Conventional versus Minimally Invasive extra-corporeal		03/05/2018	19/06/2019	29/11/2017				Both NHS Trust
		circulation in patients undergoing Cardiac Surgery: a								and Sponsor
		randomised controlled trial (COMICS)								

18/EE/0099	239606	An open label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)		13/10/2017	15/02/2019	43252	43077	27/03/2019	43552	Neither NHS Trust nor Sponsor
17/LO/1921	236323	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION		43488	07/02/2019	43445	13/05/2019	28/05/2019	30/05/2019	Sponsor
19/LO/0216	227201	A crossover, cluster randomised controlled trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit patients (SuDDICU)	19/11/2019	19/02/2019	19/09/2019	43727	23/09/2019	08/11/2019		Sponsor
18/LO/0324	220073	The VIDEO Trial:A Feasibility Randomised Control Trial of Vitrectomy Plus Standard Care Intravitreal Ranibizumab Injections versus Standard Care Intravitreal Ranibizumab injections Alone In Patients With Centre Involving Diabetic Macular Edema		16/08/2018	19/02/2019	43558	19/02/2019	15/03/2019	15/07/2019	Sponsor
18/LO/0106	170254	A prospective randomised controlled trial of hydroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies		05/01/2018	11/02/2019	09/03/2018	43510	15/02/2019	43537	Sponsor
18/WA/0239	243333	Delivering the effectiveness of early intensive versus escalation approaches for the treatment of relapsing- remitting multiple sclerosis		05/12/2018	28/01/2019	21/12/2018		08/02/2019		Sponsor
18/NE/0125	238346	A three-arm randomised controlled trial to assess the effectiveness and cost-effectiveness of reverse shoulder arthroplasty versus hemiarthroplasty versus non-surgical care for acute three and four- part fractures of the proximal humerus in patients over 65 years of age – Proximal Fracture Of the Humerus: Evaluation by Randomisation trial No.2 (PROFHER-2).	28/10/2019	12/04/2018	17/06/2019		43634	03/07/2019	08/07/2019	Neither NHS Trust nor Sponsor
18/LO/1817	244726	A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS- 8201a, an Anti-Human Epidermal Growth Factor Receptor- 2 (HER2)-Antibody Drug Conjugate (ADC), in Combination with Nivolumab, an Anti-PD-1 Antibody, for Subjects with HER2- Expressing Advanced Breast and Urothelial Cancer		28/11/2018	26/07/2019	26/04/2019	43766	13/11/2019		Sponsor
	269933	A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanilumab + standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy			21/10/2019	06/12/2019				
19/LO/0637	258758	Ripple Mapping Guided Ablation for Atrial Tachycardia: The Ripple AT-Plus Study	43770	25/03/2019	01/10/2019	14/06/2019		03/10/2019	08/10/2019	

18/NS/0145	254786			15/07/2010	07/08/2019	06/08/2019	43780	14/11/2019		27/11/2019	NHS Trust
16/105/0145	204700	A NON-INTERVENTIONAL, MULTICENTER, MULTIPLE		15/07/2019	07/06/2019	06/06/2019	43760	14/11/2019		27/11/2019	
		STUDY INVESTIGATING THE OUTCOMES AND SAFETY									
		ATEZOLIZUMAB UNDER REAL-WORLD CONDITIONS IN PATIENTS									
		TREATED IN ROUTINE CLINICAL PRACTICE									
18/LO/1007	242697	Patient-Reported Outcomes with the Accu-ChekÃ,® Solo		12/06/2018	23/05/2019			02/07/2019			Neither NHS Trust
		Micropump System vs. Multiple Daily Injection Therapy vs.									nor Sponsor
		mylife OmniPodÃ,® in Patients with Type 1 Diabetes									
19/LO/0712	257246	Comparative Health Research Outcomes of NOvel Surgery		07/11/2019	14/11/2019	07/08/2019	07/11/2019	11/12/2019			
		in prostate cancer									
18/LO/1558	248946	A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination		15/06/2018	03/04/2019	05/11/2018	13/03/2019	05/04/2019		43565	Neither NHS Trust
		with Platinum Doublet Chemotherapy and Radiotherapy for									nor Sponsor
		Participants with Unresectable, Locally Advanced Stage III									
		Non-Small Cell Lung Cancer (NSCLC)									
18/LO/0761	231087		43516	01/11/2018	01/01/2019	24/01/2019	30/01/2018	05/02/2019		05/02/2019	
		TheraSphere® Selective Internal Radiation Therapy (SIRT)									
		in the treatment of Metastatic (Liver) Neuroendocrine									
		Tumours (NETs)									
18/SC/0262	207163	Phase IIb, randomised, double-blind, placebo-controlled,		31/01/2019	25/09/2019	15/08/2018	31/01/2019				N/A
		multi-centre trial of infliximab with transcriptomic biomarker									
		and mechanism evaluation in patients with acute pancreatitis									
18/LO/1882	253030	A Phase 2, Randomized, Double-Blind, Placebo-Controlled		43224	03/04/2019	13/02/2019	43536	12/04/2019		12/04/2019	Neither NHS Trust
		Study of Abiraterone Acetate plus Prednisone with or without									nor Sponsor
		Abemaciclib in Patients with Metastatic Castration-Resistant									
		Prostate Cancer									
18/LO/0866	224730		43594	13/07/2018	28/02/2019	26/06/2018	43535	18/03/2019		43542	
		treatment after intracerebral haemorrhage: a pilot									
		randomised trial of home telemetry-guided treatment									
19/EM/0020	252705	A phase II, open-label, prospective, single-arm, study to		29/03/2019	29/05/2019	23/05/2019		01/07/2019		01/08/2019	Neither NHS Trust
		assess ability of eltrombopag to induce sustained remission									nor Sponsor
		in subjects with ITP who are refractory or relapsed after first-									
		line steroids (TAPER)									
19/LO/0095	229300	Increase in colonic PRopionate as a method of prEVENTing		23/11/2018	17/01/2019	25/01/2019		08/02/2019			Sponsor
		weight gain in young adults									
19/LO/0987	260311	Thoracoabdominal branch endoprosthesis		28/01/2019	14/10/2019						Neither NHS Trust
											nor Sponsor
18/EE/0378	248600	A Multicenter, Double-Masked, Randomized, Dose-Ranging		18/04/2019	23/05/2019	10/01/2019	43608	28/06/2019		43338	Neither NHS Trust
		Trial to Evaluate the Efficacy and Safety of Conbercept									nor Sponsor
		Intravitreal Injection in Subjects with Neovascular Age-									
		related Macular Degeneration	0.110.0100.00	1 1/0 0 /0 0 10	0.1/0.1/0.0	0=//0/22/2	00/00/00/00			00/05/000	
18/LO/1186	236886	PREvention of Stroke in Intracerebral haemorraGE survivors	04/06/2019	14/06/2018	04/01/2019	07/12/2018	06/03/2019	14/03/2019		09/05/2019	Sponsor
		with Atrial Fibrillation (PRESTIGE-AF)									
18/LO/0555	237992	s s	14/10/2019	28/08/2018	03/05/2019	19/04/2018	15/05/2019	15/05/2019		43689	Sponsor
		and late Ovarian Removal									
17/WS/0210	231280	A placebo controlled randomised trial of intravenous		11/02/2019	19/08/2019	43217	43795	43802		43819	Both NHS Trust
		lidocaine in accelerating gastrointestinal recovery after									and Sponsor
		colorectal surgery									

18/SW/0219	250410	A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AG-348 IN ADULT SUBJECTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA-AG348- C-010	01/05/2019	29/08/2018	03/01/2019	20/11/2018	21/01/2019	25/01/2019	43521	Neither NHS Trust nor Sponsor
19/SC/0031	257722	A randomised, placebo-controlled, double-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age		18/12/2018	29/04/2019		43608	23/05/2019	43608	Neither NHS Trust nor Sponsor
18/LO/1549	247067	A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of Unknown primary - CUPem		27/04/2018	14/01/2019	15/11/2018	43479	04/02/2019	43518	Neither NHS Trust nor Sponsor
18/WS/0180		response to immunotherapy in Non-small Cell Lung Cancer	01/10/2019	04/06/2019	09/07/2019	02/04/2019	43655	25/07/2019	25/07/2019	Sponsor
18/NE/0281	237312	Neuromuscular Electrical Stimulation(NMES) for the treatment of Diabetic Peripheral Neuropathy. A Randomised Controlled Trial	20/02/2019	05/12/2018	19/02/2019	43396		20/02/2019		NHS Trust
18/LO/1709	244863	PRIME-HCC: Preliminary assessment of safety and bioactivity of the Ipilimumab and Nivolumab combination prior to liver resection (LR) in hepatocellular carcinoma (HCC)	43724	09/10/2018	25/01/2019	22/11/2018	43490	07/02/2019	43525	Neither NHS Trust nor Sponsor
18/EE/0390	253601	SELECT - A multicenter, randomized, double-blind, placebo- controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension.		05/02/2019	31/05/2019	25/03/2019	23/08/2019	09/09/2019	43787	Sponsor
18/NW/0765	250220			43333	10/05/2019	01/04/2019	43733	11/10/2019		Sponsor
	272037	A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma/ CA209-9DW		12/09/2019	18/10/2019					Sponsor
	264067	A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)			02/12/2019					
18/LO/2023	253130	A double-blind, randomised, placebo controlled, adaptive design study of the efficacy, safety and pharmacokinetics of NT-814 in female subjects with moderate to severe vasomotor symptoms associated with the menopause	43601	13/11/2018	10/04/2019	18/01/2019	08/04/2019	10/04/2019	17/04/2019	No delay (met the metric)
18/WM/0199	241691	HEMOglobin transfusion threshold in Traumatic brain Injury OptimizatioN: The HEMOTION TRIAL	05/12/2019	22/10/2018	10/05/2019	02/10/2018	08/07/2019	19/08/2019	29/11/2019	Sponsor

19/LO/0879	264047	MK3475-905: A Phase 3 Randomized Study of Cystectomy		19/12/2018	09/08/2019					NHS Trust
		plus Perioperative Pembrolizumab versus Cystectomy Alone								
		in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)								
19/NW/0174	261666	A Phase III Randomized, Double-Blind, Placebo-Controlled,		43580	21/05/2019	14/06/2019	43643	43654	43664	Sponsor
		Multi-Regional, International Study of Durvalumab in								
		Combination with Gemcitabine plus Cisplatin versus Placebo								
		in Combination with Gemcitabine plus Cisplatin for Patients								
		with First-Line Advanced Biliary Tract Cancers								
18/WA/0385	254760	A Randomized, Controlled, Open-Label, Rater-Blinded,		21/11/2018	10/06/2019			10/06/2019	43629	Sponsor
		Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-								
		Week Extended Interval Dosing of Natalizumab (BG00002)								
		in Subjects With Relapsing-Remitting Multiple Sclerosis								
		Switching From Treatment With 4-Week Natalizumab								
		Standard Interval Dosing (SID) in Relation to Continued								
		SID								
		Treatment								
19/EE/0168	262098	A Phase 3, Randomized, Double-blind Study to Compare the		22/10/2018	17/07/2019	16/07/2019		06/11/2019	43811	NHS Trust
		Efficacy and Safety of Pembrolizumab (MK-3475) in								
		Combination with Lenvatinib (E7080/MK-7902) Versus								
		Pembrolizumab and Placebo as First Line Treatment for								
		Locally Advanced or Metastatic Urothelial Carcinoma in								
		Cisplatin-ineligible Participants Whose Tumors Express PD-								
		L1, and in Participants Ineligible for Any Platinum-containing								
		Chemotherapy Regardless of PD-L1 Expression (LEAP-011)								
19/LO/0201	248593	Rivaroxaban versus warfarin for stroke patients with		04/02/2019	01/07/2019	43640				Sponsor
		antiphospholipid syndrome, with or without SLE (RISAPS): a								
		randomised, controlled, open-label, phase II/III, non-								
		inferiority trial								
18/SS/0085	243640	Alpha 2 agonists for sedation to produce better outcomes		12/10/2018	08/07/2019	12/11/2018	31/01/2019	12/08/2019	19/09/2019	Sponsor
		from critical illness (A2B Trial): A randomised, parallel group,								
		allocation concealed, controlled, open, phase 3 pragmatic								
		clinical and cost- effectiveness trial with internal pilot								
19/YH/0013	255993	A Randomized, Controlled Phase 3 Study of Cabozantinib		19/11/2018	20/06/2019	09/08/2019	43433	43741	43741	Sponsor
		(XL184) in Combination with Atezolizumab versus Sorafenib								
		in Subjects with Advanced Hepatocellular Carcinoma Who								
	004740	have not received Previous Systemic Anticancer therapy.		10/10/2010	10/01/00/0		10/10/2010	00/07/00/0		
19/LO/0180	201748	A multicentre randomised controlled trial to assess the safety		18/12/2018	18/04/2019	17/04/2019	18/12/2018	08/07/2019		Neither NHS Trust
		and efficacy of adding rituximab to standard of care in								nor Sponsor
		treating acute antibody-mediated rejection in kidney								
40/00/0070	0.40000	transplantation (TAR:GET-1)		47/04/0040	40/07/0040	00/05/0040	05/07/0040	40/07/0040	40000	
19/SC/0073	246299	Segmental Tibial fractures, reamed Intramedullary nailing		17/04/2019	18/07/2019	02/05/2019	05/07/2019	19/07/2019	43668	Neither NHS Trust
		versus circular Frame external Fixation – A Feasibility study								nor Sponsor
19/WA/0005	246081	Adjuvant Treatments to the Local tumour for metastatic	43734	43359	30/07/2019	14/03/2019	30/07/2019	24/09/2019	26/09/2019	Both NHS Trust
		prostate cancer: Assessment of Novel Treatment Algorithms								and Sponsor

	1		1	I			-	г — т		
19/LO/0787	258456	A Phase 3, Multicenter, Open-Label, Randomized Study to		29/05/2019	17/07/2019					
		Evaluate the Efficacy and Safety of Fedratinib Compared to								
		Best Available Therapy in Subjects with DIPPS-Intermediate								
		or High-risk Primary Myelofibrosis, Post-Polycythemia Vera								
		Myelofibrosis or Post-Essential Thrombocythemia								
		Myelofibrosis and Previously Treated with Ruxolitinib.								
		,,								
19/LO/1449	269837	Phase 3 Randomized, Double Blind Study of Pembrolizumab			03/09/2019					Sponsor
		Plus Gemcitabine/Cisplatin versus Placebo Plus								
		Gemcitabine/Cisplatin as First-Line Therapy in Participants								
		with Advanced/Unresectable Biliary Tract Carcinoma								
19/YH/0054	258802	A pragmatic, multicentre, randomised controlled trial to		07/02/2019	20/05/2019	43560	43670	29/07/2019	27/08/2019	Sponsor
		assess the clinical and cost effectiveness of negative								
		pressure wound therapy versus usual care for surgical								
		wounds healing by secondary intention (SWHSI-2)								
19/LO/0083	201045	Safety and Efficacy of Prednisolone in Adrenal Insufficiency		07/12/2018	11/03/2019	15/02/2019	07/12/2018	05/07/2019		Both NHS Trust
		Disease (PRED-AID Study)								and Sponsor
19/SW/0028	255759	A Phase 3 Study of Itacitinib or Placebo in Combination With		43409	25/02/2019	07/05/2019	43643	03/07/2019	02/08/2019	Sponsor
		Corticosteroids as Initial Treatment for Chronic Graft-Versus-				01/00/2010			02,00,2010	
		Host Disease								
19/NE/0137	258746	An Open-Label, Multicenter, Extension Study of AG-348 in		14/01/2019	23/07/2019	12/06/2019	21/08/2019	30/08/2019	01/10/2019	Neither NHS Trust
		Adult Subjects With Pyruvate Kinase Deficiency Previously								nor Sponsor
		Enrolled in AG-348 Studies								
19/NE/0077	258955	A Multicenter, Randomized, Double-Blind, Placebo-		23/01/2019	17/04/2019	02/07/2019	16/07/2019	17/07/2019	31/07/2019	Sponsor
10/112/00/1	200000	Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects		20/01/2010	11/04/2010	02/01/2013	10/01/2010	11/01/2010	01/01/2010	oponisor
		with Follicular Lymphoma After Failure of Two or More Prior								
		Systemic Therapies								
19/LO/0196	252620	Temperature Controlled Laminar Airflow (TLA) treatment of		04/08/2018	17/06/2019	43573	01/07/2019	08/07/2019	08/07/2019	Neither NHS Trust
13/20/0130	252020	moderate to severe atopic eczema in children and		04/00/2010	17/00/2013	40070	01/01/2013	00/01/2013	00/01/2019	nor Sponsor
										nor sponsor
		adolescents-a randomized placebo controlled phase 2 study								
19/LO/0262	253945	Ripple Mapping Guided Early Ventricular Tachycardia	43600	02/10/2018	17/04/2019	43543	43581	26/04/2019	26/04/2019	
13/20/0202	200040	Ablation: A Multi-Centre Prospective Clinical Trial	43000	02/10/2010	17704/2013	40040	40001	20/04/2013	20/04/2013	
19/EE/0052	249678	A feasibility investigating different interventions for the		15/01/2019	03/04/2019	43558	43480	24/04/2019		Neither NHS Trust
		treatment of benign paroxymsmal positional vertigo in acute								nor Sponsor
		traumatic brain injury patients								
19/NW/0155	255226	A Phase 3, Open-Label, Randomized, Active-Controlled,		08/03/2019	08/03/2019	43615	43628	01/07/2019	23/07/2019	Neither NHS Trust
	200220	Multicenter Study to Evaluate the Efficacy and Safety of			00,00,2019	40010	-0020	01/01/2013	23/07/2013	nor Sponsor
		Pemigatinib Versus Gemcitabine Plus Cisplatin		1						
		Chemotherapy in First-Line Treatment of Participants With		1						
				1						
		Unresectable or Metastatic Cholangiocarcinoma With FGFR2								
40/1 0/0555	055000	Rearrangement.		40/00/0040	00/00/0040	40000	00/00/0040	00/00/0040	10755	
19/LO/0555	255609	Lateral compression type-1 fracture fixation in the elderly, a		12/08/2019	03/09/2019	43663	03/09/2019	26/09/2019	43755	Neither NHS Trust
		randomised controlled trial								nor Sponsor

19/EM/0063	253607	A Double-blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS) as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation.	43717	20/05/2019	17/06/2019	14/05/2019	43685	43686	43700	Sponsor
19/LO/0817	235449	A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer			03/09/2019	31/10/2019		07/11/2019	43758	Neither NHS Trust nor Sponsor
19/LO/0249	242498	CHOlesterol Reduction with Evolocumab and coronAry microvascuLar function	43724	13/03/2019	19/07/2019	13/06/2019	16/08/2019	20/08/2019	43719	
19/LO/0150	258058	A double-blind, placebo-controlled, randomised phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut- allergic young children 1-3 years of age		11/10/2018	29/04/2019	11/03/2019	03/05/2019	04/06/2019	04/06/2019	
19/NW/0168	249133	A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3		12/03/2019	25/06/2019	43630	16/07/2019	43693	43697	Both NHS Trust and Sponsor
19/LO/0406	260243	Boiled Peanut Immunotherapy for the treatment of Peanut Allergy: A non-inferiority study	43599		17/04/2019	17/04/2019	43573	18/04/2019	18/04/2019	No delay (met the metric)
	251991	ResidUal inflammation imaging to PredicT cardiovascular disease progression & treatment REsponse (RUPTURE)			12/04/2019			22/05/2019		Sponsor
	253405	A Phase 2b/3 study to evaluate the safety, tolerability, and effects of Livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome		26/10/2018	01/10/2019			16/10/2019	21/10/2019	N/A - 70 day met
19/LO/1153	262506	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia		18/06/2019	17/09/2019	16/09/2019	43748	17/10/2019	43784	Neither NHS Trust nor Sponsor
19/LO/1540	269196	Bariatric surgery vs. Medical care for obesity and polycystic ovarian syndrome related infertility: The BAMBINI randomised-controlled clinical trial		24/07/2019	28/10/2019	10/12/2019				
	268796	A Multicenter, Randomized, Double Blind, Placebo- Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly		24/07/2019	01/11/2019			10/11/2019	43780	
19/EE/0164	261589	T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi- cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.		12/07/2019	07/08/2019	19/07/2019	12/12/2019	18/12/2019		Sponsor
19/EM/0060	260387	A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy		15/02/2019	28/06/2019	11/06/2019	26/07/2019	30/07/2019	08/08/2019	Neither NHS Trust nor Sponsor
18/EM/0256	248467	Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction		30/08/2018	29/04/2019	22/11/2018	26/04/2019	09/05/2019	19/07/2019	Sponsor

	263312	A Phase 2 Randomized, Double-Blind, Placebo Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis		43650	30/10/2019		04/07/2019	08/11/2019		
19/LO/0138	245920	Effect of EVOlocumab on CARotid plaque composition in asymptomatic carotid artery stenosis (EVOCAR-1)	43798	30/10/2018	27/03/2019	06/03/2019	43454	43626	43711	Neither NHS Trust nor Sponsor
	261974	A Placebo-Controlled, Double-Blind, Parallel-Group, 18- Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease		27/05/2019	03/09/2019		17/09/2019	17/09/2019	23/09/2019	Neither NHS Trust nor Sponsor
19/LO/0846	266934	A Phase 1B, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety and Pharmacokinetics of Inhaled GB002, and Assess Changes in Imaging and Biomarkers in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH)		30/10/2018	25/09/2019	43725	43732	27/11/2019	27/11/2019	Sponsor
19/NS/0052	258885	A feasibility study to evaluate the use of digital technologies and artificial intelligence (AI) to enhance surgical team training and performance in the operating theatre and to improve efficiency and patient outcomes.		02/04/2019	19/09/2019	11/07/2019	43658	23/09/2019	23/09/2019	
19/LO/0431	253404	Assessment of the Accuracy of Continuous Glucose Sensors in People with Diabetes Undergoing Haemodialysis		13/12/2018	10/07/2019		43447	29/07/2019		Sponsor
	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy		17/06/2019	30/09/2019		30/09/2019	14/11/2019		EMAIL*
	252582	Randomised feasibility trial of an onward HIV disclosure intervention for 18-25 year olds living with perinatally acquired HIV	43747	28/08/2018	04/07/2019		43556	13/08/2019	13/08/2019	Trust
18/EM/0280	245964	A FIRST IN HUMAN MULTI-CENTER, OPEN LABEL, PROSPECTIVE STUDY TO EVALUATE THE SAFETY, USABILITY AND PERFORMANCE OF THE V-LAP SYSTEM	17/10/2019	05/12/2018	28/01/2019	27/01/2019	20/02/2019	06/03/2019	06/03/2019	Neither NHS Trust nor Sponsor
19/SS/0067	260562	The British Society of Endovascular Therapy ConformabLe EndoVascular Aneurysm Repair Registry	43642	17/04/2019	22/05/2019	15/05/2019	22/05/2019	11/06/2019	11/06/2019	
19/LO/0785	251807	Nonavalent prophylactic HPV vaccine (GARDASIL9) after local conservative treatment for cervical intra-epithelial neoplasia: a randomised controlled trial – The NOVEL trial		21/03/2019	27/08/2019					NHS Trust
19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): A master protocol of two randomised trials to evaluate the non-inferiority of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care	43686		18/06/2019	43672	43677	43679	43683	
19/LO/0699	252712	Tigertriever Revascularization Device Registry		01/10/2018	29/08/2019	28/08/2019	26/06/2019	25/09/2019	25/09/2019	Neither NHS Trust nor Sponsor

19/WS/0015	257033	A Phase 2, Multi-Center, Randomized, Double-Blind,		05/11/2018	10/12/2019					
19/0015	201933	Placebo Controlled, Parallel Group Study to Evaluate the		05/11/2016	10/12/2019					
		Efficacy and Safety of T-817MA in Patients with Mild								
		Cognitive Impairment Due to Alzheimer's Disease or Mild								
		Alzheimer's Disease								
19/EE/0201	264655	A Randomised, Single-blind, Placebo-controlled, Phase 1b		22/03/2019	27/06/2019	12/09/2019	43692	09/10/2019	43749	Sponsor
		Single								
		Ascending (Part A) and Multiple Dose (Part B) First-in-Man								
		Study in								
		Adult Patients with Non-transfusion-Dependent Beta-								
		Thalassaemia or Low								
		Risk Myelodysplastic Syndrome to Investigate the Safety,								
		Tolerability,								
		Pharmacokinetic and Pharmacodynamic Response of								
40/1 0/0707	050750	SLN124	40700	44/40/0040	04/07/0040	00/05/0040	10005	1005.1	 10051	
19/LO/0767	250759		43728	11/10/2018	01/07/2019	29/05/2019	43635	43654	43654	Neither NHS Trust
40/10/4450	005445	Embolization Plug System Protocol CRD 1005		00/05/0040	24/00/2010	10/00/2010				nor Sponsor
19/LO/1152	265415	A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib in participants		02/05/2019	24/09/2019	16/08/2019				Sponsor
		with previously treated locally advanced/metastatic or								
		surgically unresectable solid tumor malignancy harboring								
		activating FGFR mutations and translocations								
19/SC/0415	269249	A Phase 3 Randomized, Double-blind, Placebo-controlled		03/05/2019	20/08/2019	04/10/2019	43753	43761		Sponsor
		Study to Evaluate the Safety and Efficacy of MEDI8897, a								
		Monoclonal Antibody With an Extended Half-life Against								
		Respiratory Syncytial Virus, in Healthy Late Preterm and								
		Term Infants (MELODY)							 	-
19/SC/0416	269256	A phase 2/3 randomised, double-blind, palivizumab-		05/03/2019	21/08/2019		43752	43761		Sponsor
		controlled study to evaluate the safety of MEDI8897, a								
		monoclonal antibody with an extended half-life against								
	241385	respiratory syncytial virus, in high risk children (MEDLEY) An Open-Label, Multi-Centre, Randomised Study to		12/12/2019	22/05/2019			01/07/2019		Neither NHS Trust
	241300	Investigate Integrase Inhibitor Versus Boosted Protease		12/12/2016	22/05/2019			01/07/2019		nor Sponsor
		Inhibitor Antiretroviral Therapy for Patients with Advanced								
		HIV Disease								
	237494	Re-evaluating Optimal Vaccine Schedules Against Ebola		31/08/2018	31/07/2019		43713	43717	43733	N/A
					25/07/2019			07/08/2019		Neither NHS Trust
										nor Sponsor
	259840	IPX203-B16-02			26/11/2019					
19/EM0258	266702	Fluids Exclusively Enteral From Day 1			28/11/2019	13/09/2019				
19/EE/0326	270902	A randomised double-blind placebo controlled phase 3 trial to		43755	28/10/2019					
		evaluate the efficacy and safety of estetrol for the treatment								
		of moderate to severe vasomotor symptoms in								
4.0/0/0/07	040000	postmenopausal women (E4 Comfort Study I)		00/00/0040	44/40/0040	42422	42040	40/40/0040	40040	
18/WS/0187	242800	Retrospective and prospective international EKoSoNic®		06/06/2019	11/12/2019	43433	43812	12/12/2019	43812	
		registry Of the treatment and Clinical OUTcomes of patients with Pulmonary Embolism								
		with Fullfondry Endouisin								

19/LO/1726	269978	A diagnostic accuracy study evaluating point of care gastric			19/12/2019	18/12/2019				
10/20/11/20	200010	lipase enhanced pH test strip to confirm correct nasogastric			13/12/2013	10/12/2013				
		tube position in newborn infant								
19/LO/1290	262104	Non-Invasive Continuous Cardiac Output Monitoring in	43762	43507	03/10/2019	02/10/2019	43741	03/10/2019		
		Newborn Infant Study								
19/LO/1363	263653	Stryker ASSIST Registry		19/03/2019	19/11/2019	19/11/2019	43791	43796		
18/LO/1203	242451	ORBITA-2: A placebo-controlled trial of percutaneous	43504	11/07/2018	21/01/2019	31/08/2018	16/10/2019	01/02/2019	01/02/2019	Neither NHS Trust
		coronary intervention for the relief of stable angina (Objective								nor Sponsor
		Randomized Blinded Investigation with optimal medical								
		Therapy of Angioplasty in stable angina 2)								
19/LO/0067	256498	The effect of cross-linked sodium hyaluronate on the quality	43636	43445	15/03/2019		15/03/2019	12/04/2019	43567	
		of optical coherence tomography imaging								
	214739	Does Interleukin-1 Receptor Antagonist Improve Outcome		17/04/2019	15/10/2019					Sponsor
		following aneurysmal Subarachnoid Haemorrhage (aSAH)?								
		A Phase III trial								
19/NW/0462	251756	Chronic Endometriosis and Recurrent Miscarriage - The		10/10/2019	10/10/2019	20/08/2019				N/A
		CERM Trial								
19/SW/0078	253353	A pilot study to investigate the effect of phosphodiesterase		21/03/2019	23/05/2019	16/05/2019	43608	21/06/2019	43640	
		inhibitors on chorioretinal blood flow using optical coherence								
40/1 0/0405	0.4005.4	tomography angiography		00/40/0040	4.4/00/0040	05/00/0040	10000	40.000	10000	
19/LO/0185	246354	Characterising the natural history of mucosal metabolism		20/12/2018	14/06/2019	25/02/2019	43630	43669	43669	Neither NHS Trust
4.0/1.0/4.000	000454	during colorectal anastomotic healing		00/00/0040	00/05/0040	44/05/0040	40500			nor Sponsor
18/LO/1022	233151	An open-label, randomised, phase II trial of ruCaparib		06/02/2019	29/05/2019	14/05/2019	43502			Sponsor
		combined with Nivolumab +/- Ipilimumab to augment								
		response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube								
		cancer								
18/WA/0417	251207	"Phase 3 randomized placebo controlled trial of		31/01/2019	15/04/2019	43578	43518	43706	43718	Both NHS Trust
10/17/0417	201201	Atezolizumab in combination with paclitaxel and carboplatin			10/04/2013	43370	40010	43700	43710	and Sponsor
		in women with advanced/recurrent endometrial cancer"								
19/HRA/0634	258886	Mobile learning resources as a tool for improving	24/02/2019	43493	30/01/2019	28/01/2019	08/02/2019	08/02/2019		
		clinician's ability to break bad news: A quasi-randomised								
		controlled trial								
19/NW/0135	252254	An International Randomised Clinical Trial of Therapeutic		26/06/2019	15/07/2019	17/05/2019				Sponsor
		Interventions with the Potential to Improve Outcome in								'
		Adults with Acute Myeloid Leukaemia and High Risk								
		Myelodysplasia Undergoing Allogeneic Stem Cell								
		Transplantation.								
19/LO/1320	255755	Mechanisms of adverse effects of long-acting beta-agonists		06/08/2019	13/08/2019	02/12/2019				Trust
		in asthma (MAELABA)								
19/LO/0881	257058	Feasibility study of OnTrack - a digital system for upper limb		16/04/2019	11/07/2019	43656		43677		Sponsor
		rehabilitation after stroke								
18/LO/1400	250545	A prospective study to assess the efficacy and safety of the		18/07/2018	30/10/2019					Sponsor
		BlueWind RENOVA iStimâ, ¢ system for the treatment of								
		patients diagnosed with overactive bladder								
19/WA/0077	256787	Optimal Vascular Access for Elderly Haemodialysis Patients:	43644	12/02/2019	13/06/2019	16/04/2019	12/02/2019	17/06/2019	14/06/2019	
		a randomised controlled study comparing tunnelled								
		haemodialysis catheters and native arteriovenous fistulae								

19/LO/0282	259274	Investigating the utility of a complex film intervention about		15/01/2019	12/03/2019	43536	43480	43550		Neither NHS Trust
		MS delivered online								nor Sponsor
19/EM/0202		assessment of LACTIN-V use in a cohort of pregnant women	43724	15/05/2019	04/09/2019	43712	43719	43719	43720	No delay (met the metric)
		at increased risk of preterm birth.								
18/LO/1101	233138	Health in Pregnancy	43768	11/05/2018	22/07/2019	02/08/2018	26/09/2019	43734	43734	Neither NHS Trust
										nor Sponsor